Cheng AL - Search Results

1

Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.

Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. Kelley RK, et al. Among authors: cheng al. Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3. Future Oncol. 2020. PMID: 32491932

2

Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.

Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2002;62(4):305-12. doi: 10.1159/000065061. Oncology. 2002. PMID: 12138237

3

Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Hsu C, et al. Among authors: cheng al. Oncology. 2003;65(3):242-9. doi: 10.1159/000074477. Oncology. 2003. PMID: 14657598

4

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: cheng al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

5

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Hsu C, Cheng JC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng jc. J Formos Med Assoc. 2004 Jul;103(7):483-95. J Formos Med Assoc. 2004. PMID: 15318270 Review.

6

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2005;68(4-6):538-47. doi: 10.1159/000086998. Epub 2005 Jul 20. Oncology. 2005. PMID: 16037687

7

Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Yeh KH, et al. Among authors: cheng al. Oncology. 2005;69(1):88-95. doi: 10.1159/000087304. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088236 Clinical Trial.

8

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Lin CC, et al. Among authors: cheng al. Invest New Drugs. 2007 Feb;25(1):77-84. doi: 10.1007/s10637-006-9004-9. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937079 Clinical Trial.

9

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Cheng AL, et al. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. Lancet Oncol. 2009. PMID: 19095497 Clinical Trial.

10

Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design.

Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng cc. Contemp Clin Trials. 2010 Jan;31(1):55-61. doi: 10.1016/j.cct.2009.08.002. Epub 2009 Sep 6. Contemp Clin Trials. 2010. PMID: 19737631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

823 results

Search Page

Filters